Sofinicline

Sofinicline

SCHEMBL2080581

Clc1cc(N2C[C@@H]3CN[C@@H]3C2)cnc1Cl.O=S(=O)(O)O

nearest known ligand 0.85

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CHRNA4CHRNB2

The experimentally established mechanism targets of Sofinicline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CHRNB2 known ✓ P17787 20/20 0.85
CHRNA4 known ✓ P43681 20/20 0.85
CHRNB4 P30926 20/20 0.85
CHRNA3 P32297 20/20 0.85

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sofinicline SCHEMBL3913123 0.99 CHRNB2 (0.83) CHRNB2CHRNB4CHRNA3CHRNA4
Sofinicline SCHEMBL2078738 0.95 CHRNB2 (0.81) CHRNB2CHRNB4CHRNA3CHRNA4
Sofinicline SCHEMBL5100670 0.95 CHRNB2 (0.81) CHRNB2CHRNB4CHRNA3CHRNA4
Sofinicline SCHEMBL650490 0.92 CHRNB2 (1.00) CHRNB2CHRNB4CHRNA3CHRNA4
Sofinicline SCHEMBL22754711 0.92 CHRNB2 (1.00) CHRNB2CHRNB4CHRNA3CHRNA4
Sofinicline SCHEMBL1560706 0.92 CHRNB2 (1.00) CHRNB2CHRNB4CHRNA3CHRNA4
Sofinicline SCHEMBL650488 0.92 CHRNB2 (1.00) CHRNB2CHRNB4CHRNA3CHRNA4
Sofinicline SCHEMBL4436795 0.92 CHRNB2 (1.00) CHRNB2CHRNB4CHRNA3CHRNA4
Sofinicline SCHEMBL650489 0.92 CHRNB2 (1.00) CHRNB2CHRNB4CHRNA3CHRNA4
Sofinicline SCHEMBL5096637 0.91 CHRNB2 (0.97) CHRNB2CHRNB4CHRNA3CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902371-B2 (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate ABBOTT LABORATORIES (US) 2011-03-08 US disclosed
EP-1771451-B1 (1S,5S)-3-(5,6-DICHLOROPYRIDIN-3-YL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE BENZENESULFONATE ABBOTT LAB (US) 2010-09-08 EP disclosed
US-20090203664-A1 (1S,5S)-3-(5,6-DICHLORO-3-PYRIDINYL)-3,6- DIAZABICYCLO[3.2.0]HEPTANE ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
US-20090198067-A1 (1S,5S)-3-(5,6-Dichloropyridin-3-YL)-3,6-Diazabicyclo[3.2.0]Heptane Benzenesulfonate ABBOTT LABORATORIES (US) 2009-08-06 US disclosed
US-7538226-B2 (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane ABBOTT LABORATORIES (US) 2009-05-26 US disclosed
US-7498444-B2 (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate ABBOOTT LABORATORIES (US) 2009-03-03 US disclosed
US-7354937-B2 (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane ABBOTT LABORATORIES (US) 2008-04-08 US disclosed
US-7351833-B2 (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate ABBOTT LABORATORIES (US) 2008-04-01 US disclosed
US-20080070891-A1 (1S,5S)-3-(5,6-DICHLORO-3-PYRIDINYL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE ABBVIE INC. 2008-03-20 US disclosed
US-20080004448-A1 (1S,5S)-3-(5.6-DICHLOROPYRIDIN-3-YL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE BENZENESULFONATE ABBVIE INC. 2008-01-03 US disclosed
US-20060035936-A1 (1S,5S)-3-(5,6-DICHLORO-3-PYRIDINYL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE ABBVIE INC. 2006-02-16 US disclosed
US-20060035937-A1 (1S,5S)-3-(5,6-dichloropyridin-3-YL)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate ABBVIE INC. 2006-02-16 US disclosed
US-20050261348-A1 (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent ABBOTT LABORATORIES 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035937-A1 (1S,5S)-3-(5,6-dichloropyridin-3-YL)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate DHPS, HCN2, DCPS CHRNB2 2936/4885CHRNA4 2769/4885CHRNB4 3327/4885
US-20080004448-A1 (1S,5S)-3-(5.6-DICHLOROPYRIDIN-3-YL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE BENZENESULFONATE DHPS, HCN2, DCPS CHRNB2 2933/4885CHRNA4 2761/4885CHRNB4 3314/4885
US-20080070891-A1 (1S,5S)-3-(5,6-DICHLORO-3-PYRIDINYL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE CHRNA6, CHRNA5, CHRNA3 CHRNB2 12/4885CHRNA4 7/4885CHRNB4 17/4885
US-20090203664-A1 (1S,5S)-3-(5,6-DICHLORO-3-PYRIDINYL)-3,6- DIAZABICYCLO[3.2.0]HEPTANE CHRNA6, CHRNA5, CHRNA3 CHRNB2 12/4885CHRNA4 7/4885CHRNB4 17/4885
US-20090198067-A1 (1S,5S)-3-(5,6-Dichloropyridin-3-YL)-3,6-Diazabicyclo[3.2.0]Heptane Benzenesulfonate DHPS, HCN2, DCPS CHRNB2 2936/4885CHRNA4 2769/4885CHRNB4 3327/4885
US-20060035936-A1 (1S,5S)-3-(5,6-DICHLORO-3-PYRIDINYL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE CHRNA6, CHRNA5, CHRNA3 CHRNB2 12/4885CHRNA4 7/4885CHRNB4 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.